Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
22.5M
-
Shares change
-
-3.33M
-
Total reported value, excl. options
-
$16.3M
-
Value change
-
-$3.18M
-
Number of buys
-
13
-
Number of sells
-
-13
-
Price
-
$0.72
Significant Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2025
41 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.5M shares
of 55.6M outstanding shares and own 40.55% of the company stock.
Largest 10 shareholders include GILEAD SCIENCES, INC. (9.11M shares), Bain Capital Life Sciences Investors, LLC (4.57M shares), Merck & Co., Inc. (1.48M shares), TAKEDA PHARMACEUTICAL CO LTD (1.48M shares), MORGAN STANLEY (1.16M shares), VANGUARD GROUP INC (1.14M shares), FMR LLC (884K shares), AJU IB Investment Co., Ltd. (668K shares), GEODE CAPITAL MANAGEMENT, LLC (379K shares), and Balyasny Asset Management L.P. (254K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.